Skip to content

Checked

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NCT06172296 on ClinicalTrials.gov

Study listings come from ClinicalTrials.gov, where sponsors register and update their own studies. A listing does not mean a study is safe or effective, and DatenUS does not recommend any study. Talk with your doctor before joining a clinical trial, and use ClinicalTrials.gov for contact details and full eligibility rules.

Status
Recruiting
Phase
Phase 3
Interventional
Planned enrollment
478
Participants, all sites
U.S. sites
158
In 47 states

Study details

Conditions
Ganglioneuroblastoma, Nodular, Neuroblastoma
Sponsor
National Cancer Institute (NCI) (National Institutes of Health)
Ages
Up to 30 years
Sex
All
Healthy volunteers
Not accepted
Start
04/19/2024
Primary completion (expected)
12/31/2029
Last updated by sponsor
10/26/2026

Full eligibility rules, contacts and site names: NCT06172296 on ClinicalTrials.gov

Where the study has sites

Cities with at least one listed U.S. site. Some sites may not be enrolling yet.

  • Alabama: Birmingham, Mobile
  • Arizona: Mesa, Phoenix, Tucson
  • Arkansas: Little Rock
  • California: Los Angeles (3), Oakland (2), Sacramento (2), Downey, Duarte, Loma Linda, Long Beach, Madera, Orange, Palo Alto, San Diego, San Francisco
  • Colorado: Aurora
  • Connecticut: Hartford, New Haven
  • Delaware: Wilmington
  • District of Columbia: Washington D.C.
  • Florida: Orlando (3), Miami (2), Fort Lauderdale, Fort Myers, Gainesville, Hollywood, Jacksonville, St. Petersburg, West Palm Beach
  • Georgia: Atlanta, Savannah
  • Hawaii: Honolulu
  • Illinois: Chicago (3), Oak Lawn, Park Ridge, Peoria, Springfield
  • Indiana: Indianapolis (2)
  • Iowa: Des Moines, Iowa City
  • Kansas: Wichita
  • Kentucky: Lexington, Louisville
  • Louisiana: New Orleans
  • Maine: Bangor, Scarborough
  • Maryland: Baltimore (3), Bethesda
  • Massachusetts: Boston (2)
  • Michigan: Ann Arbor, Detroit, Grand Rapids, Kalamazoo, Royal Oak
  • Minnesota: Minneapolis (2), Rochester
  • Mississippi: Jackson
  • Missouri: St Louis (2), Columbia, Kansas City
  • Nebraska: Omaha (2)
  • Nevada: Las Vegas
  • New Hampshire: Lebanon
  • New Jersey: New Brunswick (2), Hackensack, Morristown, Newark, Paterson
  • New Mexico: Albuquerque
  • New York: New York (2), Albany, Buffalo, Mineola, New Hyde Park, Rochester, Syracuse, The Bronx, Valhalla
  • North Carolina: Charlotte (2), Asheville, Chapel Hill, Durham, Greenville, Winston-Salem
  • North Dakota: Fargo
  • Ohio: Cleveland (2), Akron, Cincinnati, Columbus, Dayton, Toledo
  • Oklahoma: Oklahoma City, Tulsa
  • Oregon: Portland (2)
  • Pennsylvania: Philadelphia (2), Allentown, Danville, Pittsburgh
  • Rhode Island: Providence
  • South Carolina: Charleston, Columbia, Greenville
  • South Dakota: Sioux Falls
  • Tennessee: Nashville (2), Knoxville, Memphis
  • Texas: San Antonio (3), Dallas (2), Houston (2), Lubbock (2), Austin, Corpus Christi, El Paso, Fort Worth
  • Utah: Salt Lake City
  • Vermont: Burlington
  • Virginia: Charlottesville, Portsmouth
  • Washington: Seattle, Spokane, Tacoma
  • West Virginia: Huntington, Morgantown
  • Wisconsin: Green Bay, Madison, Marshfield, Milwaukee

More studies on the same topic

Frequently asked questions

What does recruiting mean?
Recruiting means the study is currently enrolling participants. Not yet recruiting means it has been registered but has not started enrolling. Enrolling by invitation means participants are selected by the study team rather than through open enrollment.
How do I join a clinical trial?
Read the full eligibility criteria and contact information on ClinicalTrials.gov, then talk with your doctor about whether a study may be right for you. The study team decides who can enroll.

Source: ClinicalTrials.gov, National Library of Medicine · Last updated 10/26/2026